Trial results

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

NCT06803888 on ClinicalTrials.gov · last registry update 2026-09-03

Closed to new participants; the 140 already enrolled are still being followed. Due to report 1 July 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Mean percentage total body weight loss at Week 52. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

ACTIVE_NOT_RECRUITING

Phase

P4

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Ali Aminian

Sponsor type

Other

Enrollment

140

Started

2025-01-29

Primary completion

2027-07-01 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Mean percentage total body weight loss at Week 52

Conditions studied

Obesity and Obesity-related Medical Conditions

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.